Replies to post #166536 on Anavex Life Sciences Corp (AVXL)

[XenaLives]

If 20% have the gene variants, then they are probably still in the trial because they are sleeping better, can calm down better, or some other reason.

Cognitive improvement is most desired, but it will not be the only reason to take 2-73.

It also won't be the only reason to approve this drug.

All IMO - of course...

[Steady_T]

I have spent some time recently looking at the data provided by the company.

If you take out the 20% then the remaining subject are declining at a much slower rate or holding at the same level.

That is way better than the SOC no matter how you slice it.

That has to be replicated in the new trial. If it is then 2-73 is a major hit. It is not the miracle drug that it has sometimes been portrayed. It is however, a huge step forward in the treatment of AD.

If 2-73 has similar positive effects on other CNS diseases then it becomes a blockbuster deluxe.